IPM Take
Parkinson’s disease has never lacked biological targets. It has lacked proof that hitting those targets changes what happens to the patient. Alpha-synuclein is perhaps the clearest example: it sits at the heart of Parkinson’s pathology, yet attempts to turn that knowledge into disease modification have repeatedly been harder than the mechanism suggested.
AC Immune’s latest ACI-7104 data therefore deserve attention without celebration. Every treated participant generated an immune response after three immunisations, antibodies reached the cerebrospinal fluid, and exploratory findings were consistent with target engagement. That is exactly what an active immunotherapy needs to show at this stage. It is also nowhere near enough to show that Parkinson’s progression has slowed.
Executive Summary
AC Immune reported week-100 results from Part 1 of the Phase II VacSYn study of ACI-7104, an active immunotherapy targeting pathological alpha-synuclein in early Parkinson’s disease.
Part 1 included 34 participants, with 25 receiving ACI-7104 and nine receiving placebo. The company reported that the study met its primary safety, tolerability and immunogenicity endpoints. All treated participants developed antibodies against the immunising alpha-synuclein antigen after three immunisations, and antibody penetration into cerebrospinal fluid was demonstrated.
The study was not designed or powered to establish clinical efficacy. Exploratory biomarker analyses showed a signal involving total alpha-synuclein in CSF, while exploratory correlations suggested relationships between antibody levels and disease-activity measures. AC Immune plans to discuss the expansion programme with FDA in early 2027.
Why it matters
- For patients, disease modification remains the unresolved Parkinson’s question. Existing therapies can improve symptoms dramatically, but they do not reliably stop the underlying neurodegenerative process. For researchers and regulators, ACI-7104 tests whether active immunisation can produce sustained alpha-synuclein-directed immunity without the logistical burden of repeatedly administered antibody therapy.
- The public-policy issue comes later but should already be visible. Vaccination sounds operationally simple, but a neurodegenerative vaccine would still require early diagnosis, specialist selection, biomarker infrastructure and long-term monitoring. If intervention works best early, late diagnosis becomes an access failure rather than merely a diagnostic inconvenience.
The attraction of a Parkinson’s vaccine is easy to understand. Instead of repeatedly administering a therapeutic antibody, an active immunotherapy attempts to teach the patient’s own immune system to generate antibodies against pathological alpha-synuclein. In theory, that could create a durable treatment effect with a very different administration burden.
VacSYn has now cleared an important biological hurdle. The immune system responded, the antibodies reached the central nervous system, and the treatment was reported as generally well tolerated through week 100. Those are legitimate achievements for an early clinical programme.
What the trial has not shown is more important for patients. It has not established that tremor improves, gait remains stable, cognition declines more slowly or independence is prolonged. Part 1 was specifically designed around safety and immunogenicity, not clinical efficacy. The temptation to describe successful target engagement as disease modification should therefore be resisted.
That restraint matters because Parkinson’s research has repeatedly demonstrated that changing a biologically interesting marker does not guarantee that neurodegeneration follows. Part 2 of VacSYn will have to carry a much heavier burden. It needs to show whether the immune response can produce measurable clinical activity and whether those effects are durable enough to justify progression to Phase III.
The vaccine has taught the immune system something. The next trial has to show whether Parkinson’s disease listens.
